Binge (Eating) Disorders Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

Binge (Eating) Disorders Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

“Binge (Eating) Disorders Pipeline Insight, 2020′

(Albany, US) DelveInsight has launched a new report on “Binge (Eating) Disorders Pipeline Insight, 2020” 

Binge Disorders Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Binge Disorders market. A detailed picture of the Binge Disorders pipeline landscape is provided, which includes the disease overview and Binge Disorders treatment guidelines.

The assessment part of the report embraces in-depth Binge Disorders commercial assessment and clinical assessment of the Binge Disorders pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge Disorders collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


List of top key players in binge eating disorder drug market report are: –

● Roche

● Chronos Therapeutics

● Heptares

● Novo Nordisk

● Omeros Corp

● Sunovion Pharmaceuticals

● Opiant Pharmaceuticals


Request for Free sample report:

Scope of the report

  • The Binge Disorders report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Binge Disorders across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Binge Disorders therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Binge Disorders research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Binge Disorders.


Binge-eating disorder is a serious eating disorder in which you frequently consume unusually large amounts of food and feel unable to stop eating.

Almost everyone overeats on occasion, such as having seconds or thirds of a holiday meal. But for some people, excessive overeating that feels out of control and becomes a regular occurrence crosses the line to binge-eating disorder.

When you have binge-eating disorder, you may be embarrassed about overeating and vow to stop. But you feel such a compulsion that you can’t resist the urges and continue binge eating. If you have binge-eating disorder, treatment can help.


Most people with binge-eating disorder are overweight or obese, but you may be at a normal weight. Behavioral and emotional signs and symptoms of binge-eating disorder include:

  • Eating unusually large amounts of food in a specific amount of time, such as over a two-hour period
  • Feeling that your eating behavior is out of control
  • Eating even when you’re full or not hungry
  • Eating rapidly during binge episodes
  • Eating until you’re uncomfortably full
  • Frequently eating alone or in secret
  • Feeling depressed, disgusted, ashamed, guilty or upset about your eating
  • Frequently dieting, possibly without weight loss


Request for Free sample report:


Key Questions

  • What are the current options for Binge Disorders treatment?
  • How many companies are developing therapies for the treatment of Binge Disorders?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Binge Disorders?
  • How many Binge Disorders emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Binge Disorders?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Binge Disorders market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Binge Disorders? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Binge Disorders therapies?
  • What are the clinical studies going on for Binge Disorders and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Binge Disorders?
  • How many patents are granted and pending for the emerging therapies for the treatment of Binge Disorders?


Request for Free sample report:


Table of Contents:

1. Report Introduction

2. Binge Disorders 

2.1. Overview

2.2. History 

2.3. Binge Disorders Symptoms

2.4. Causes


2.6. Binge Disorders Diagnosis 

2.6.1. Diagnostic Guidelines

3. Binge Disorders Current Treatment Patterns

3.1. Binge Disorders Treatment Guidelines

4. Binge Disorders – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Binge Disorders companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Binge Disorders Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Binge Disorders Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Binge Disorders Late Stage Products (Phase-III)

7. Binge Disorders Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Binge Disorders Discontinued Products

13. Binge Disorders Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report? 

14. Binge Disorders Key Companies

15. Binge Disorders Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Binge Disorders Unmet Needs

18. Binge Disorders Future Perspectives

19. Binge Disorders Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 


Request for Detailed TOC: 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States